Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 20/20 | 0.64 |
| ▸ | SGK1 | O00141 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ULK1 | O75385 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | GRK2 | P25098 | 1/20 | 0.50 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.50 |
| ▸ | GRK3 | P35626 | 1/20 | 0.50 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.50 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.50 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16110615 | 1.00 | MAPK1 (0.64) | MAPK1SGK1ROCK2ULK1CDK2 | |
| SCHEMBL16110612 | 0.89 | MAPK1 (0.58) | MAPK1 | |
| SCHEMBL16110611 | 0.89 | MAPK1 (0.58) | MAPK1 | |
| SCHEMBL16110727 | 0.89 | MAPK1 (0.59) | MAPK1 | |
| SCHEMBL16110726 | 0.89 | MAPK1 (0.59) | MAPK1 | |
| SCHEMBL16964870 | 0.87 | MAPK1 (0.83) | MAPK1 | |
| SCHEMBL16964872 | 0.87 | MAPK1 (0.83) | MAPK1 | |
| SCHEMBL16964593 | 0.87 | MAPK1 (0.63) | MAPK1 | |
| SCHEMBL14893167 | 0.87 | MAPK1 (0.63) | MAPK1 | |
| SCHEMBL14895601 | 0.87 | MAPK1 (0.63) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023865-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140296203-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296203-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK10, MAP3K1 | MAPK1 1/4885SGK1 197/4885ROCK2 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.